These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. How to combine the molecular profile with the clinicopathological profile of urothelial neoplastic lesions. van der Kwast TH Scand J Urol Nephrol Suppl; 2008 Sep; (218):175-84. PubMed ID: 18815932 [TBL] [Abstract][Full Text] [Related]
23. [Expression of apoptosis inhibitor gene Livin in bladder transitional cell carcinoma and clinical implication thereof]. Song T; Hong BF; Gao JP; Cai W; Wang CY Zhonghua Yi Xue Za Zhi; 2007 Mar; 87(12):806-7. PubMed ID: 17565859 [TBL] [Abstract][Full Text] [Related]
24. Differential expression of vascular endothelial growth factor165b in transitional cell carcinoma of the bladder. Das K; Zhao Y; Sugiono M; Lau W; Tan PH; Cheng C Urol Oncol; 2007; 25(4):317-21. PubMed ID: 17628298 [TBL] [Abstract][Full Text] [Related]
25. [Prognostic factors and markers used in urothelial carcinoma of the bladder]. Billerey C; Vieillefond A Ann Pathol; 1999; 19(5 Suppl):S107-9. PubMed ID: 10599469 [No Abstract] [Full Text] [Related]
26. Real-time quantitative analysis for human telomerase reverse transcriptase mRNA and human telomerase RNA component mRNA expressions as markers for clinicopathologic parameters in urinary bladder cancer. Takihana Y; Tsuchida T; Fukasawa M; Araki I; Tanabe N; Takeda M Int J Urol; 2006 Apr; 13(4):401-8. PubMed ID: 16734859 [TBL] [Abstract][Full Text] [Related]
27. Evidence for the early onset of aberrant promoter methylation in urothelial carcinoma. Dhawan D; Hamdy FC; Rehman I; Patterson J; Cross SS; Feeley KM; Stephenson Y; Meuth M; Catto JW J Pathol; 2006 Jul; 209(3):336-43. PubMed ID: 16639696 [TBL] [Abstract][Full Text] [Related]
28. Overexpression of cyclooxygenase-2 (COX-2) in the mouse urinary bladder induces the expression of immune- and cell proliferation-related genes. Wang X; Colby JK; Rengel RC; Fischer SM; Clinton SK; Klein RD Mol Carcinog; 2009 Jan; 48(1):1-13. PubMed ID: 18444251 [TBL] [Abstract][Full Text] [Related]
29. Expression of chicken ovalbumin upstream promoter-transcription factor I (COUP-TFI) in bladder transitional cell carcinoma. Ham WS; Lee JH; Yu HS; Choi YD Urology; 2008 Oct; 72(4):921-6. PubMed ID: 18387660 [TBL] [Abstract][Full Text] [Related]
30. FISH: a tool we really need? Pycha A Eur Urol; 2007 Sep; 52(3):630-2; discussion 633-5. PubMed ID: 17416454 [No Abstract] [Full Text] [Related]
31. Sensitivity and specificity of p53 protein detection by immunohistochemistry in patients with urothelial bladder carcinoma. Salinas-Sánchez AS; Atienzar-Tobarra M; Lorenzo-Romero JG; Sánchez-Sánchez F; Giménez-Bachs JM; Donate-Moreno MJ; Pastor-Navarro H; Hernández-Millán I; Segura-Martín M; Escribano-Martínez J Urol Int; 2007; 79(4):321-7. PubMed ID: 18025850 [TBL] [Abstract][Full Text] [Related]
32. Association of TSC1/hamartin, 14-3-3sigma, and p27 expression with tumor outcomes in patients with pTa/pT1 urothelial bladder carcinoma. Mhawech-Fauceglia P; Alvarez V; Fischer G; Beck A; Herrmann FR Am J Clin Pathol; 2008 Jun; 129(6):918-23. PubMed ID: 18480009 [TBL] [Abstract][Full Text] [Related]
33. Combination analysis of hypermethylated Wnt-antagonist family genes as a novel epigenetic biomarker panel for bladder cancer detection. Urakami S; Shiina H; Enokida H; Kawakami T; Kawamoto K; Hirata H; Tanaka Y; Kikuno N; Nakagawa M; Igawa M; Dahiya R Clin Cancer Res; 2006 Apr; 12(7 Pt 1):2109-16. PubMed ID: 16609023 [TBL] [Abstract][Full Text] [Related]
34. Molecular markers for detection, surveillance and prognostication of bladder cancer. Vrooman OP; Witjes JA Int J Urol; 2009 Mar; 16(3):234-43. PubMed ID: 19298346 [TBL] [Abstract][Full Text] [Related]
35. Transitional cell carcinomas and nonurothelial carcinomas of the urinary bladder differ in the promoter methylation status of the caveolin-1, hDAB2IP and p53 genes, but not in the global methylation of Alu elements. Kunze E; Von Bonin F; Werner C; Wendt M; Schlott T Int J Mol Med; 2006 Jan; 17(1):3-13. PubMed ID: 16328005 [TBL] [Abstract][Full Text] [Related]
36. Assessment by M-FISH of karyotypic complexity and cytogenetic evolution in bladder cancer in vitro. Ratliff TL J Urol; 2005 Nov; 174(5):2065. PubMed ID: 16217396 [No Abstract] [Full Text] [Related]
37. Rapid identification of UCA1 as a very sensitive and specific unique marker for human bladder carcinoma. Wang XS; Zhang Z; Wang HC; Cai JL; Xu QW; Li MQ; Chen YC; Qian XP; Lu TJ; Yu LZ; Zhang Y; Xin DQ; Na YQ; Chen WF Clin Cancer Res; 2006 Aug; 12(16):4851-8. PubMed ID: 16914571 [TBL] [Abstract][Full Text] [Related]
38. Survivin mRNA expression in urine as a biomarker for patients with transitional cell carcinoma of bladder. Hou JQ; He J; Wen DG; Chen ZX; Zeng J Chin Med J (Engl); 2006 Jul; 119(13):1118-20. PubMed ID: 16834932 [No Abstract] [Full Text] [Related]
39. In vitro and in vivo effects of CpG-Oligodeoxynucleotides (CpG-ODN) on murine transitional cell carcinoma and on the native murine urinary bladder wall. Olbert PJ; Schrader AJ; Simon C; Dalpke A; Barth P; Hofmann R; Hegele A Anticancer Res; 2009 Jun; 29(6):2067-76. PubMed ID: 19528466 [TBL] [Abstract][Full Text] [Related]
40. Epigenetic markers as promising prognosticators for bladder cancer. Kim YK; Kim WJ Int J Urol; 2009 Jan; 16(1):17-22. PubMed ID: 18721202 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]